THE EFFECT OF BETARGIN ON THE INDICATORS OF CHRONIC SYSTEMIC IN- FLAMMATION, ENDOTHELIAL DYSFUNCTION AND ANTIOXIDANT DEFENSE IN PATIENTS WITH CORONARY HEART DISEASE CONCURRENT WITH NON-ALCO- HOLIC FATTY LIVER DISEASE


  • Yu. Manusha Ukrainian Medical Stomatological Academy, Ukraine
  • V. Zhdan Ukrainian Medical Stomatological Academy, Ukraine
  • K. Ischeikin Ukrainian Medical Stomatological Academy, Ukraine
  • Yu. Kazakov Ukrainian Medical Stomatological Academy, Ukraine
Keywords: coronary heart disease, chronic systemic inflammation, endothelial dysfunction, non-alcoholic fatty liver disease, betargin.

Abstract

THE EFFECT OF BETARGIN ON THE INDICATORS OF CHRONIC SYSTEMIC IN- FLAMMATION, ENDOTHELIAL DYSFUNCTION AND ANTIOXIDANT DEFENSE IN PATIENTS WITH CORONARY HEART DISEASE CONCURRENT WITH NON-ALCO- HOLIC FATTY LIVER DISEASE

References

1. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Nonalcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9:126– 33

2. Shi A. ,Tao Z.,Wei P. & Zhao J., 2016. Epidemiological aspects of heart. Exp Ther Med diseases.12(3), pp. 1645–1650.

3. Icksoo Lee. Betaine is a positive regulator of mitochondrial respiration. Biochemical and Biophysical Research Com- munications. 2015; 456: 621-625.

4. Manush Yu, Kazakov YM, Mamontov TV, Shlikova OA, Chekalina N.I. Application of betargin in the treatment of stable coronary heart disease and non-alcoholic fatty liver disease. Bulletin: Problems of Biology and Medicine. 2018; 4: 1 (146): 102-107.

5. Meng Q, Cooney M, Yepuri N, Cooney RN. L-arginine attenuates Interleukin-1β (IL-1β) induced Nuclear Factor Kap- pa-Beta (NF-κB) activation in Caco-2 cells. PLOS One. 2017; 12(3): 120-8.

6. Hurjui DM, Nita O, Graur LI, Micalache L. Non-alcoholic fatty liver disease is associated with cardiovascular risk fac- tors of metabolic syndrome. Rev Med Chir Soc Med Nat Lasi. 2012Jul;116(3):692-9.
Published
2019-12-20
How to Cite
Manusha, Y., Zhdan, V., Ischeikin, K., & Kazakov, Y. (2019). THE EFFECT OF BETARGIN ON THE INDICATORS OF CHRONIC SYSTEMIC IN- FLAMMATION, ENDOTHELIAL DYSFUNCTION AND ANTIOXIDANT DEFENSE IN PATIENTS WITH CORONARY HEART DISEASE CONCURRENT WITH NON-ALCO- HOLIC FATTY LIVER DISEASE. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 3(2), 27-28. https://doi.org/10.29256/v.03.02.2019.escbm05